Wolfgang Janni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wolfgang Janni has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Brigitte Rack
Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, Munich, Germany
13 shared publications Dorothea Rjosk
I. Frauenklinik, Klinikum der Ludwig-Maximilians-Universtitaet, Muenchen, Germany
6 shared publicationsBarbara Strobl
5 shared publicationsStephan Braun
Universitaetsklinikum fuer Frauenheilkunde, Leopold-Franzens-Universitaet, Innsbruck, Austria
5 shared publications- Thomas Wolfram Paul Friedl
Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
5 shared publications - Andreas Schneeweiss
National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
4 shared publications
Latest Publications
- 1 October 2018
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 12 (05) , 398-403
SOP – Wissenschaftlich publizieren
Aller Anfang ist schwer und das gilt besonders für die Wissenschaft. Ist die erste Studie abgeschlossen, wollen die Ergebnisse natürlich auch veröffentlicht werden. Im 1. Teil dieser SOP (Frauenheilkunde up2date 2018; 12: 312 – 316) haben Sie die wichtigsten Schritte zur Literatursuche und Manuskripterstellung kennengelernt – der 2. Teil führt Sie nun vom Editieren über den Einreichungs- und Begutachtungsprozess bis zur finalen Annahme.
- 1 October 2018
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 12 (05) , 398-403
SOP – Wissenschaftlich publizieren
Aller Anfang ist schwer und das gilt besonders für die Wissenschaft. Ist die erste Studie abgeschlossen, wollen die Ergebnisse natürlich auch veröffentlicht werden. Im 1. Teil dieser SOP (Frauenheilkunde up2date 2018; 12: 312 – 316) haben Sie die wichtigsten Schritte zur Literatursuche und Manuskripterstellung kennengelernt – der 2. Teil führt Sie nun vom Editieren über den Einreichungs- und Begutachtungsprozess bis zur finalen Annahme.
- 1 August 2018
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 12 (04) , 312-316
SOP – Wissenschaftlich publizieren
Aller Anfang ist schwer und das gilt besonders für die Wissenschaft. Ist die erste Studie abgeschlossen, wollen die Ergebnisse natürlich auch veröffentlicht werden. Von Literatursuche über Manuskripterstellung und Feinschliff, von der Einreichung bis zur finalen Annahme – dieser 2-teilige Beitrag liefert Ihnen eine umfassende Einstiegshilfe in das wissenschaftliche Publizieren.
- 1 August 2018
- Published by Georg Thieme Verlag KG in Frauenheilkunde up2date
- Vol. 12 (04) , 312-316
SOP – Wissenschaftlich publizieren
Aller Anfang ist schwer und das gilt besonders für die Wissenschaft. Ist die erste Studie abgeschlossen, wollen die Ergebnisse natürlich auch veröffentlicht werden. Von Literatursuche über Manuskripterstellung und Feinschliff, von der Einreichung bis zur finalen Annahme – dieser 2-teilige Beitrag liefert Ihnen eine umfassende Einstiegshilfe in das wissenschaftliche Publizieren.
- 26 September 2017
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 14 (03) , 147-159
Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens
Seit über 30 Jahren findet regelmäßig (in den letzten 6 Jahren alle 2 Jahre) die internationale St. Gallen-Konsensuskonferenz zur Behandlung von Patientinnen mit primärem Mammakarzinom statt. Die Ergebnisse des internationalen St. Gallen-Konsensus-Panels wurden auch dieses Jahr wieder von einer deutschen Arbeitsgruppe führender Brustkrebsexperten für den Klinikalltag in Deutschland diskutiert. Fünf der Brustkrebsexperten aus Deutschland sind zugleich Mitglieder des diesjährigen St. Gallen-Panels. Der Vergleich der St. Gallen-Empfehlungen mit den jährlich aktualisierten Therapieempfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-Mamma 2017) und der aktuell im Jahre 2017 abgestimmten S3-Leitlinie ist sinnvoll. Die Empfehlungen des St. Gallen-Panels stellen ein Meinungsbild von Experten unterschiedlicher Länder und Fachdisziplinen dar, wohingegen S3-Leitlinie und AGO-Empfehlungen evidenzbasiert sind. Die diesjährige 15. St. Gallen-Konsensuskonferenz stand unter dem Motto „Escalating and De-Escalating“, das sich durch alle Therapiebereiche zog, die zur Abstimmung standen. Ziel war es, Patientinnen individuellere Therapieoptionen anzubieten und das Risiko einer Über- bzw. Untertherapie zu vermeiden. The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists. Five of the breast cancer specialists from Germany were also members of this year’s St. Gallen panel. A comparison between the St. Gallen recommendations and the annually updated treatment guidelines of the Gynecologic Oncology Group (AGO 2017) and the S3-guideline agreed upon in 2017 is useful. The recommendations of the St. Gallen panel represent an international crosssection of opinions of experts from different countries and different disciplines, while the S3-guideline and AGO guidelines are evidence-based. The motto of this year’s 15th St. Gallen Conference was “Escalating and De-Escalating“. The rationale behind this concept was to promote more individualized treatment and thereby reduce overtreatment as well as undertreatment. * St. Gallen Panel Expert
- 26 September 2017
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 14 (03) , 147-159
Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens
Seit über 30 Jahren findet regelmäßig (in den letzten 6 Jahren alle 2 Jahre) die internationale St. Gallen-Konsensuskonferenz zur Behandlung von Patientinnen mit primärem Mammakarzinom statt. Die Ergebnisse des internationalen St. Gallen-Konsensus-Panels wurden auch dieses Jahr wieder von einer deutschen Arbeitsgruppe führender Brustkrebsexperten für den Klinikalltag in Deutschland diskutiert. Fünf der Brustkrebsexperten aus Deutschland sind zugleich Mitglieder des diesjährigen St. Gallen-Panels. Der Vergleich der St. Gallen-Empfehlungen mit den jährlich aktualisierten Therapieempfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-Mamma 2017) und der aktuell im Jahre 2017 abgestimmten S3-Leitlinie ist sinnvoll. Die Empfehlungen des St. Gallen-Panels stellen ein Meinungsbild von Experten unterschiedlicher Länder und Fachdisziplinen dar, wohingegen S3-Leitlinie und AGO-Empfehlungen evidenzbasiert sind. Die diesjährige 15. St. Gallen-Konsensuskonferenz stand unter dem Motto „Escalating and De-Escalating“, das sich durch alle Therapiebereiche zog, die zur Abstimmung standen. Ziel war es, Patientinnen individuellere Therapieoptionen anzubieten und das Risiko einer Über- bzw. Untertherapie zu vermeiden. The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists. Five of the breast cancer specialists from Germany were also members of this year’s St. Gallen panel. A comparison between the St. Gallen recommendations and the annually updated treatment guidelines of the Gynecologic Oncology Group (AGO 2017) and the S3-guideline agreed upon in 2017 is useful. The recommendations of the St. Gallen panel represent an international crosssection of opinions of experts from different countries and different disciplines, while the S3-guideline and AGO guidelines are evidence-based. The motto of this year’s 15th St. Gallen Conference was “Escalating and De-Escalating“. The rationale behind this concept was to promote more individualized treatment and thereby reduce overtreatment as well as undertreatment. * St. Gallen Panel Expert
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e23061
LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer.
E23061 Background: To reach distant sites, CTC overcome metabolic stress and acquire a mesenchymal phenotype. So we assessed the pro survival function of liver kinase B1 (LKB1) a cellular metabolic stress controller, in combination with the EMT transcription factor Zinc finger E-box binding homeobox factor 1 (ZEB1) and stem cell markers e.g. CD44 in EpCAM negative CTC. Tumor spheroids and targeted si-RNA knockdown of LKB1 were analyzed in two breast cancer cell lines to support transcriptomic data. Methods: CTC were isolated from whole blood of 27 metastatic breast cancer patients. 17 age matched healthy donors were negative control. All patients were analyzed with CellSearch system to detect EpCAM positive CTC, which were eliminated by immunodepletion (AdnaTest BreastCancerSelect Kit, TATAA Biocenter) together with CD45 positive white blood cells (Miltenyi Biotec). RNA transcripts were quantified by qPCR (TaqMan Gene Expression Assay, ThermoFischer Scientific) and the relative expression was calculated by the 2-DCtmethod. EpCAM negative CTC and spheroids were analyzed by immunofluorescence. Data were analyzed by non-parametric statistical tests. Results: According to the CellSearch system, most patients (74%, n = 20) were CTC negative. 20% of this sub-group showed enhanced levels of ZEB1, 15% of LKB1, and 40% of stem cell markers. ZEB1 and LKB1 were never co-expressed, while there was an almost significant association between enhanced ZEB1 and stem cell marker expression (p = 0.053). Immunofluorescence analysis on single CTC confirmed the transcriptomic result. MDA-MB 231 cell lines, normally negative for LKB1 and unable to grow in suspension, showed the ability to generate spheroids only if LKB1 expression was activated. Targeted knockdown of LKB1 confirmed these results. Conclusions: CellSearch system negative patients present a heterogeneous CTC population with enhanced levels of ZEB1, CD44, or LKB1. While ZEB1 and CD44 might be highly expressed in cells that already have entered EMT, LKB1 overexpression could represent the response to metabolic stress induced in the early phase of intravasation Hence, LKB1 might represent a novel therapeutic target to chase CTC and prevent metastasis.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e23061
LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer.
E23061 Background: To reach distant sites, CTC overcome metabolic stress and acquire a mesenchymal phenotype. So we assessed the pro survival function of liver kinase B1 (LKB1) a cellular metabolic stress controller, in combination with the EMT transcription factor Zinc finger E-box binding homeobox factor 1 (ZEB1) and stem cell markers e.g. CD44 in EpCAM negative CTC. Tumor spheroids and targeted si-RNA knockdown of LKB1 were analyzed in two breast cancer cell lines to support transcriptomic data. Methods: CTC were isolated from whole blood of 27 metastatic breast cancer patients. 17 age matched healthy donors were negative control. All patients were analyzed with CellSearch system to detect EpCAM positive CTC, which were eliminated by immunodepletion (AdnaTest BreastCancerSelect Kit, TATAA Biocenter) together with CD45 positive white blood cells (Miltenyi Biotec). RNA transcripts were quantified by qPCR (TaqMan Gene Expression Assay, ThermoFischer Scientific) and the relative expression was calculated by the 2-DCtmethod. EpCAM negative CTC and spheroids were analyzed by immunofluorescence. Data were analyzed by non-parametric statistical tests. Results: According to the CellSearch system, most patients (74%, n = 20) were CTC negative. 20% of this sub-group showed enhanced levels of ZEB1, 15% of LKB1, and 40% of stem cell markers. ZEB1 and LKB1 were never co-expressed, while there was an almost significant association between enhanced ZEB1 and stem cell marker expression (p = 0.053). Immunofluorescence analysis on single CTC confirmed the transcriptomic result. MDA-MB 231 cell lines, normally negative for LKB1 and unable to grow in suspension, showed the ability to generate spheroids only if LKB1 expression was activated. Targeted knockdown of LKB1 confirmed these results. Conclusions: CellSearch system negative patients present a heterogeneous CTC population with enhanced levels of ZEB1, CD44, or LKB1. While ZEB1 and CD44 might be highly expressed in cells that already have entered EMT, LKB1 overexpression could represent the response to metabolic stress induced in the early phase of intravasation Hence, LKB1 might represent a novel therapeutic target to chase CTC and prevent metastasis.
- 4 June 2016
- Published by Springer Nature in Breast Cancer
- Vol. 24 (2) , 319-325
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial
- 4 June 2016
- Published by Springer Nature in Breast Cancer
- Vol. 24 (2) , 319-325
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial
- 1 June 2016
- Vol. 36 (6) , 3123-30
Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
Circulating tumor cells (CTCs) in women with breast cancer are an indication of prognosis before starting systemic treatment. The aim of this study was the evaluation of cytokine profiles as marker for CTC involvement. The analysis of CTCs, the time of blood sampling and the methodology were prospectively designed. There were two groups of patients: 100 women with a positive result for presence of CTCs and 100 women negative for CTCs. These groups were matched into pairs by tumor factors and survival/death. A multi-array ELISA was used to screen T-helper cell (Th) 2 cytokines. The results were analyzed by Spearman correlation coefficient and Mann-Whitney U-test. In patients who were CTC-negative, expression of interleukin-8 (IL-8) and IL-13 was increased (p=0.017 and p=0.045, respectively) if they were negative for progesterone receptor. In patients who died from their tumor, correlation between hormone receptor negativity and an increase in IL-4 was found. IL-5 was increased in patients with lymph node-positive and human epidermal growth factor receptor 2 (HER2)-positive disease (p=0.042). Moreover IL-4 was increased in patients with progesterone receptor-positive and estrogen receptor-negative status (p=0.024). Furthermore, the level of IL-6 was increased in patients with tumor grade G3 without progesterone receptor expression. Th2 cytokines are significantly modified in patients who are CTC-negative and progesterone receptor-positive. We suppose that an increase of IL-4 depends on hormone receptor status. In literature, a correlation between IL-4 and resistance to apoptosis is described. We suspect that IL-4 is responsible for the poor outcome of these cases.
- 1 June 2016
- Vol. 36 (6) , 3123-30
Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
Circulating tumor cells (CTCs) in women with breast cancer are an indication of prognosis before starting systemic treatment. The aim of this study was the evaluation of cytokine profiles as marker for CTC involvement. The analysis of CTCs, the time of blood sampling and the methodology were prospectively designed. There were two groups of patients: 100 women with a positive result for presence of CTCs and 100 women negative for CTCs. These groups were matched into pairs by tumor factors and survival/death. A multi-array ELISA was used to screen T-helper cell (Th) 2 cytokines. The results were analyzed by Spearman correlation coefficient and Mann-Whitney U-test. In patients who were CTC-negative, expression of interleukin-8 (IL-8) and IL-13 was increased (p=0.017 and p=0.045, respectively) if they were negative for progesterone receptor. In patients who died from their tumor, correlation between hormone receptor negativity and an increase in IL-4 was found. IL-5 was increased in patients with lymph node-positive and human epidermal growth factor receptor 2 (HER2)-positive disease (p=0.042). Moreover IL-4 was increased in patients with progesterone receptor-positive and estrogen receptor-negative status (p=0.024). Furthermore, the level of IL-6 was increased in patients with tumor grade G3 without progesterone receptor expression. Th2 cytokines are significantly modified in patients who are CTC-negative and progesterone receptor-positive. We suppose that an increase of IL-4 depends on hormone receptor status. In literature, a correlation between IL-4 and resistance to apoptosis is described. We suspect that IL-4 is responsible for the poor outcome of these cases.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11529
Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.
11529 Background: The presence of circulating tumor cells (CTCs) before chemotherapy (CTX) is an independent prognostic marker for reduced survival in early breast cancer (EBC). In addition, recent results suggest that persisting CTCs immediately after adjuvant CTX indicate poor prognosis. There is a lack of data regarding the best use of CTC numbers for risk stratification. Here, we evaluated different methods to calculate changes in CTC counts during the course of CTX and their prognostic value with respect to overall survival (OS). Methods: The German SUCCESS A trial is a phase III study in which patients with high-risk EBC were first randomized to adjuvant CTX treatment with 3 cycles of epirubicin-fluorouracil-cyclophosphamide followed by either 3 cycles of docetaxel or 3 cycles of gemcitabine-docetaxel. CTC enumeration was performed using the FDA-approved CellSearch System (Janssen Diagnostics, LLC). Patient outcome in terms of OS was analyzed using univariate log-rank tests and Cox regression models. Information on CTC status before and after CTX was available for 1507 (40.1 %) of 3754 randomized patients. Results: Overall, 311 patients had at least one CTC before CTX (median 1 CTC, range 1 – 827) and were included in the analyses. 79 (25.4%) of these patients had at least one CTC after CTX (median 1, range 1 – 124). A quantitative assessment with the change in number of CTCs (before and after CTX) as continuous variable significantly predicted OS (hazard ratio [HR] 0.995, 95% confidence interval [CI] 0.992-0.998, p = 0.002). Surprisingly CTC clearance (no vs. yes) was not significantly associated with OS (HR 1.508, 95% CI 0.783- 2.904, p = 0.216). However, patients that showed an increase in CTC number from before to after CTX had significantly shorter OS than patients with no such increase (HR 3.545, 95% CI 1.490- 8.434, p = 0.004). Conclusions: Both a quantitative assessment in terms of changes in CTC numbers from before to after CTX and a qualitative measure according to whether or not there was an increase in CTC number showed a significant association with overall survival in EBC patients. Clinical trial information: NCT02181101.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11529
Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.
11529 Background: The presence of circulating tumor cells (CTCs) before chemotherapy (CTX) is an independent prognostic marker for reduced survival in early breast cancer (EBC). In addition, recent results suggest that persisting CTCs immediately after adjuvant CTX indicate poor prognosis. There is a lack of data regarding the best use of CTC numbers for risk stratification. Here, we evaluated different methods to calculate changes in CTC counts during the course of CTX and their prognostic value with respect to overall survival (OS). Methods: The German SUCCESS A trial is a phase III study in which patients with high-risk EBC were first randomized to adjuvant CTX treatment with 3 cycles of epirubicin-fluorouracil-cyclophosphamide followed by either 3 cycles of docetaxel or 3 cycles of gemcitabine-docetaxel. CTC enumeration was performed using the FDA-approved CellSearch System (Janssen Diagnostics, LLC). Patient outcome in terms of OS was analyzed using univariate log-rank tests and Cox regression models. Information on CTC status before and after CTX was available for 1507 (40.1 %) of 3754 randomized patients. Results: Overall, 311 patients had at least one CTC before CTX (median 1 CTC, range 1 – 827) and were included in the analyses. 79 (25.4%) of these patients had at least one CTC after CTX (median 1, range 1 – 124). A quantitative assessment with the change in number of CTCs (before and after CTX) as continuous variable significantly predicted OS (hazard ratio [HR] 0.995, 95% confidence interval [CI] 0.992-0.998, p = 0.002). Surprisingly CTC clearance (no vs. yes) was not significantly associated with OS (HR 1.508, 95% CI 0.783- 2.904, p = 0.216). However, patients that showed an increase in CTC number from before to after CTX had significantly shorter OS than patients with no such increase (HR 3.545, 95% CI 1.490- 8.434, p = 0.004). Conclusions: Both a quantitative assessment in terms of changes in CTC numbers from before to after CTX and a qualitative measure according to whether or not there was an increase in CTC number showed a significant association with overall survival in EBC patients. Clinical trial information: NCT02181101.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS634
The DETECT study concept: Individualized therapy of metastatic breast cancer.
TPS634 Background: Circulating tumor cells (CTCs) are found in blood samples of patients with early as well as metastatic breast cancer (MBC). The prognostic and predictive value of CTCs, whose phenotype may differ from the primary tumor, has been described already. However, treatment decisions often still result from the primary tumor’s phenotype without considering CTC-characteristics. The importance of CTC phenotypes for guiding therapeutic decisions will be investigated within the DETECT studies. Methods: The DETECT study concept provides a prospective, multicenter, open-label clinical trial program comprising two phase III studies (DETECT III and V) and one phase II study (DETECT IV). Women with HER2-negative MBC are tested for CTCs and their HER2-phenotype. CTC detection is performed by the FDA-approved CellSearch System (Janssen Diagnostics, Raritan, USA). Patients with HER2-positive CTCs are recruited into DETECT III and randomized to a physician’s choice chemo- or endocrine therapy +/- additional HER2-targeted treatment with lapatinib. Patients with only HER2-negative CTCs are included in DETECT IV. Postmenopausal women with hormone-receptor (HR)-positive MBC are treated with everolimus and a physician’s choice endocrine therapy (DETECT IVa); women with triple-negative MBC or HR-positive tumors with indication for chemotherapy receive eribulin (DETECT IVb). In DETECT V/CHEVENDO, which started in autumn 2015, women with HER2- and HR-positive MBC are randomized to a dual HER2-directed therapy with pertuzumab and trastuzumab plus either chemotherapy or endocrine therapy. CTC-presence is not obligatory in DETECT V, but translational research projects focus on CTC-enumeration and the assessment of marker expression on CTCs in order to calculate an endocrine-responsiveness-score, which will be evaluated regarding to its suitability to predict treatment success. Perspective: Changes in the dynamic of CTCs during therapy and their HER2-phenotype may influence following therapy decisions. The DETECT study program evaluates the prognostic and predictive role of CTCs as well as a CTC based therapy and enables the establishment of a more personalized therapy for patients with MBC. Clinical trial information: NCT01619111, NCT 02035813, NCT02344472.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , TPS634
The DETECT study concept: Individualized therapy of metastatic breast cancer.
TPS634 Background: Circulating tumor cells (CTCs) are found in blood samples of patients with early as well as metastatic breast cancer (MBC). The prognostic and predictive value of CTCs, whose phenotype may differ from the primary tumor, has been described already. However, treatment decisions often still result from the primary tumor’s phenotype without considering CTC-characteristics. The importance of CTC phenotypes for guiding therapeutic decisions will be investigated within the DETECT studies. Methods: The DETECT study concept provides a prospective, multicenter, open-label clinical trial program comprising two phase III studies (DETECT III and V) and one phase II study (DETECT IV). Women with HER2-negative MBC are tested for CTCs and their HER2-phenotype. CTC detection is performed by the FDA-approved CellSearch System (Janssen Diagnostics, Raritan, USA). Patients with HER2-positive CTCs are recruited into DETECT III and randomized to a physician’s choice chemo- or endocrine therapy +/- additional HER2-targeted treatment with lapatinib. Patients with only HER2-negative CTCs are included in DETECT IV. Postmenopausal women with hormone-receptor (HR)-positive MBC are treated with everolimus and a physician’s choice endocrine therapy (DETECT IVa); women with triple-negative MBC or HR-positive tumors with indication for chemotherapy receive eribulin (DETECT IVb). In DETECT V/CHEVENDO, which started in autumn 2015, women with HER2- and HR-positive MBC are randomized to a dual HER2-directed therapy with pertuzumab and trastuzumab plus either chemotherapy or endocrine therapy. CTC-presence is not obligatory in DETECT V, but translational research projects focus on CTC-enumeration and the assessment of marker expression on CTCs in order to calculate an endocrine-responsiveness-score, which will be evaluated regarding to its suitability to predict treatment success. Perspective: Changes in the dynamic of CTCs during therapy and their HER2-phenotype may influence following therapy decisions. The DETECT study program evaluates the prognostic and predictive role of CTCs as well as a CTC based therapy and enables the establishment of a more personalized therapy for patients with MBC. Clinical trial information: NCT01619111, NCT 02035813, NCT02344472.
- 1 January 2016
- Published by Elsevier
- p. 163-183
Gestationsbedingte Trophoblasterkrankungen
- 26 November 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (11) , 986-988
Update zur Studienlandschaft. Zirkulierende Tumorzellen beim metastasierten Mammakarzinom
Das primäre Mammakarzinom gilt schon zum Zeitpunkt der Erstdiagnose als eine potenziell systemische Erkrankung. Die kontinuierliche Streuung von isolierten Tumorzellen (ITZ) in die Blutbahn von Patientinnen mit Mammakarzinom stellt ein lang bekanntes Phänomen dar [1]. Nach der Hypothese der metastatischen Ineffizienz (metastatic inefficiency) werden die meisten dieser Zellen vom Immunsystem oder durch mechanische Scherkräfte des Blutes eliminiert [2], [3]. Eine kleine Subpopulation kann jedoch langfristig im Blut oder in sogenannten „secondary homing sites“ persistieren und gilt als Surrogatmarker der minimalen Tumorresterkrankung (minimal residual disease, MRD) und somit einer späteren Fernmetastasierung.
- 26 November 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (11) , 986-988
Update zur Studienlandschaft. Zirkulierende Tumorzellen beim metastasierten Mammakarzinom
Das primäre Mammakarzinom gilt schon zum Zeitpunkt der Erstdiagnose als eine potenziell systemische Erkrankung. Die kontinuierliche Streuung von isolierten Tumorzellen (ITZ) in die Blutbahn von Patientinnen mit Mammakarzinom stellt ein lang bekanntes Phänomen dar [1]. Nach der Hypothese der metastatischen Ineffizienz (metastatic inefficiency) werden die meisten dieser Zellen vom Immunsystem oder durch mechanische Scherkräfte des Blutes eliminiert [2], [3]. Eine kleine Subpopulation kann jedoch langfristig im Blut oder in sogenannten „secondary homing sites“ persistieren und gilt als Surrogatmarker der minimalen Tumorresterkrankung (minimal residual disease, MRD) und somit einer späteren Fernmetastasierung.